Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 33

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 16
Chunk 33
---
 contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.The following tables summarize balances and activity in each of the product revenue allowance and reserve categories for the years ended December 31, 2024 and December 31, 2023:(In thousands)Contractual AdjustmentsGovernment RebatesReturnsTotalBalance at December 31, 2023$156 $1,084 $232 $1,472 Current provisions relating to sales in the current year1,300 2,593 399 4,292 Adjustments relating to prior years(39)(711)(45)(795)Payments/returns relating to sales in the current year(1,079)(1,239)— (2,318)Payments/returns relating to sales in the prior years(85)(373)(97)(555)Balance at December 31, 2024$253 $1,354 $489 $2,096 (In thousands)Contractual AdjustmentsGovernment RebatesReturnsTotalBalance at December 31, 2022$65 $573 $133 $771 Current provisions relating to sales in the current year1,079 2,086 2,182 5,347 Adjustments relating to prior years— (237)(77)(314)Payments/returns relating to sales in the current year(938)(1,003)(1,958)(3,899)Payments/returns relating to sales in the prior years(50)(335)(48)(433)Balance at December 31, 2023$156 $1,084 $232 $1,472 

F-19

Total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:(In thousands)December 31, 2024December 31, 2023Reduction of accounts receivable$124 $151 Component of accrued expenses 1,972 1,321 Total revenue-related reserves$2,096 $1,472 The following table presents changes in our contract assets, which consisted of accounts receivable, net: (In thousands)December 31, 2024December 31, 2023Beginning balance$2,810 $2,206    Additions (1)39,973 31,855    Deductions (1)(38,674)(31,251)Ending balance$4,109 $2,810